系统性红斑狼疮患者肺炎球菌疫苗接种:一项多中心安慰剂对照随机双盲研究
该多中心随机安慰剂对照双盲试验比较了系统性红斑狼疮(SLE)稳定期患者单用23价多糖疫苗与7价肺炎球菌结合疫苗后序贯23价多糖疫苗的免疫原性和安全性。主要终点为第28周对两种疫苗共有的7种血清型中至少5种产生应答的应答率,两组分别为72%(18/25)和76%(13/17),差异无统计学意义(p=0.75)。结论认为序贯接种安全且短期免疫有效,但不优于单用多糖疫苗。
要点
- 第28周主要终点应答率:安慰剂-PPS组72%(18/25) vs PnCj-PPS组76%(13/17),p=0.75。
- 第52周持续应答率:安慰剂-PPS组72%(13/18) vs PnCj-PPS组77%(10/13),p=0.77。
- SLE flare:6例患者共报告9次 flare,安慰剂-PPS组4次 vs PnCj-PPS组2次,p=0.70。
核心结论
- 序贯接种PnCj疫苗后PPS疫苗在SLE患者中安全且显示短期免疫效力,但不优于单用PPS疫苗。
研究设计与样本
- 多中心随机安慰剂对照双盲试验,比较单用PPS疫苗(安慰剂-PPS组)与PnCj疫苗后24周序贯PPS疫苗(PnCj-PPS组)。
- 改良意向治疗分析纳入安慰剂-PPS组25例和PnCj-PPS组17例SLE稳定期患者。
- 主要终点为第28周对PPS和PnCj共有的7种血清型(4、6B、9V、14、18C、19F和23F)中至少5种产生应答的应答率。
主要发现
- 第28周主要终点应答率:安慰剂-PPS组72%(18/25) vs PnCj-PPS组76%(13/17),p=0.75。
- 第52周时,第28周达到主要终点的患者中仍对≥5/7种共有血清型应答的比例:安慰剂-PPS组72%(13/18) vs PnCj-PPS组77%(10/13),p=0.77。
- 两组OPA应答率无差异。
- 6例患者共报告9次SLE flare,安慰剂-PPS组4次 vs PnCj-PPS组2次,p=0.70。
临床怎么用
- 原文结论认为序贯接种PnCj后PPS安全且短期免疫有效,但不优于单用PPS疫苗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Invasive pneumococcal disease and respiratory tract infections are both frequent and severe in patients with systemic lupus erythematosus (SLE). This study aimed to compare the immunological efficacy and safety of pneumococcal vaccination with the 23-valent polysaccharide (PPS) vaccine alone to a sequential immunization with the 7-valent pneumococcal conjugate (PnCj) vaccine followed by PPS in patients with SLE and stable diseaase. METHODS: Multicenter randomized placebo-controlled double-blind trial: PPS vaccine alone (placebo-PPS group) or PnCj vaccine followed by PPS vaccine (PnCj-PPS group) 24weeks later. The primary endpoint was the rate of responders at week 28 to at least 5 of the 7 serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) shared by both PPS and PnCj. Pneumococcal IgG antibodies' opsonophagocytic activity (OPA) were also assessed. RESULTS: Twenty-five patients in the placebo-PPS group and 17 in the PnCj-PPS group were included in a modified intention-to-treat analysis. The primary endpoint was reached in 72% (18/25) in the placebo-PPS and 76% (13/17) in the PnCj-PPS group (p=0.75). There was no difference in the rates of responders with OPA. At week 52, 13/18 (72%) patients in the placebo-PPS group and 10/13 (77%) patients in the PnCj-PPS group (p=0.77) that met the primary endpoint at week 28 were still responders to ≥5/7 serotypes shared by both PPS and PnCj vaccines. Nine SLE flares were reported in 6 patients (4 in the placebo-PPS and 2 in the PnCj-PPS groups respectively, p=0.70). CONCLUSION: Sequential administration of PnCj vaccine followed by PPS vaccine is safe and shows short-term immunological efficacy in patients with SLE but was not superior to the PPS vaccine alone. TRIAL REGISTRATION: www.clinicaltrials.gov, NCT NCT00611663.
引用
- Grabar S, Groh M, Bahuaud M, et al. Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study. Vaccine. 2017. PMID: 28784280. doi:10.1016/j.vaccine.2017.07.094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。